← Live radar Archive

πŸ“‘ RADAR REPORT

Wednesday, 18 November 2026 Β· data as of 2026-11-18 12:48 UTC
ACTIVE TRIALS8,741
P3 READOUTS Β· 14D41
P3 READOUTS Β· 30D131
CHANGES Β· 7D100
LATE >6 MONTHS46%
Get the Radar Report by email β€” a weekly digest, free.

Phase 3 readouts due Β· next 14 days

41 trials with an exact primary-completion date in the next two weeks (131 in the next 30 days).
DateTrialSponsorAreaNvs. original plan
2026-11-18 est.POETYK SjS-1Bristol-Myers Squibb $BMYImmuno774+0.0 mo
2026-11-18 est.Drugs-SNPsMedicine Invention Design, IncOncology600+30.0 mo
2026-11-20 est.PembrolizumabMerck Sharp & Dohme LLC $MRKOncology990+17.1 mo
2026-11-21 est.Cabergoline tabletsChangchun GeneScience Pharmaceutical Co., Ltd.Cardio-Met382+14.0 mo
2026-11-23 est.Investigational varicella vaccineGlaxoSmithKline $GSKInfectious750+4.4 mo
2026-11-23 est.dTpaGlaxoSmithKline $GSKInfectious102β€”
2026-11-24 est.KarXTKaruna Therapeutics, Inc., a Bristol Myers Squibb companyNeuro406+0.8 mo
2026-11-24 est.AvelumabEMD Serono Research & Development Institute, Inc. $MRK.DEOncology205+33.9 mo
2026-11-24 est.177Lu-DOTATATE injectionHTA Co., Ltd.Other184+0.0 mo
2026-11-25 est.ICP-332 TabletsBeijing InnoCare Pharma Tech Co., Ltd.Immuno552+0.0 mo
2026-11-25 est.rilzabrutinibSanofi $SNYCardio-Met3-0.2 mo
2026-11-26 est.RUBYTesaro, Inc.Oncology785+60.0 mo
2026-11-26 est.MT1013Shaanxi Micot Pharmaceutical Technology Co., Ltd.Cardio-Met424+0.0 mo
2026-11-28 est.Yellow fever vaccine (live)Sanofi $SNYInfectious2440+3.7 mo
2026-11-29 est.RimegepantPfizer $PFENeuro723+5.9 mo
2026-11-30 est.D-0502InventisBio Co., LtdOncology640+0.0 mo
2026-11-30 est.AtezolizumabHoffmann-La Roche $RO.SWOncology382-8.1 mo
2026-11-30 est.Drug:WD-890Zhejiang Wenda Pharma Technology LTD.Immuno375β€”
2026-11-30 est.A166Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. $6990.HKOncology365+12.0 mo
2026-11-30 est.SL1002Saol Therapeutics IncNeuro150+0.0 mo
2026-11-30 est.Neuroncell-EXCytopeutics Sdn. Bhd.Cardio-Met80+21.7 mo
2026-11-30 est.GS1191-0445 injectionGritgen Therapeutics Co., Ltd.Rare50+0.0 mo
2026-11-30 est.TS-172 20~60 mg/dayTaisho Pharmaceutical Co., Ltd.Other34β€”
2026-11-30 est.LeniolisibPharming Technologies B.V.Other15+29.7 mo
2026-11-30 est.AVTX-803 (L-Fucose)AUG TherapeuticsOther4+47.0 mo

Registry changes Β· last 7 days

Phase 3 / 2-3 trials whose ClinicalTrials.gov record changed (status, readout date, enrollment, sites), plus stops and results posted.
TrialSponsorChange
Nogapendekin alfa inbakicept (NAI)ImmunityBio, Inc.Not yet recruiting β†’ Withdrawn
NMS-03305293Nerviano Medical SciencesActive, not recruiting β†’ Terminated
AB-3028Arsenal Biosciences, Inc.Active, not recruiting β†’ Terminated
Debio 4326Debiopharm International SAreadout 2026-10 β†’ 2026-10-09 (+0.3 mo)
VIGILANTGlaxoSmithKline $GSKreadout 2029-04-30 β†’ 2029-04-02 (-0.9 mo)
MAESTRA 2Incyte Corporation $INCYreadout 2028-11-15 β†’ 2027-10-12 (-13.1 mo)
ACSNovartis Pharmaceuticals $NVSreadout 2027-02-11 β†’ 2027-01-16 (-0.9 mo)
SPN-812Supernus Pharmaceuticals, Inc.readout 2026-09 β†’ 2026-12 (+3.0 mo)
ICM ADX-2191 injectionAldeyra Therapeutics, Inc.readout 2026-12 β†’ 2029-12 (+36.0 mo)
DuraSTARGlaxoSmithKline $GSKreadout 2029-12-12 β†’ 2030-03-13 (+3.0 mo)
WILL-EMIHoffmann-La Roche $RO.SWreadout 2027-04-30 β†’ 2027-10-06 (+5.2 mo)
Citicoline eye drops 2%Omikron Italia S.r.l.readout 2026-04-01 β†’ 2029-07-01 (+39.0 mo)
RASolute 303Revolution Medicines, Inc. $RVMDreadout 2028-06 β†’ 2028-04 (-2.0 mo)
Sinovac rabies vaccineSinovac Biotech Co., Ltdreadout 2026-09-30 β†’ 2026-07-15 (-2.5 mo)
ZasocitinibTakeda $TAKreadout 2033-01-24 β†’ 2034-07-03 (+17.2 mo)
IPAX BrIGHTTelix Pharmaceuticals (Innovations) Pty Limitedreadout 2027-07 β†’ 2028-07 (+12.0 mo)
OPTIMARegeneron Pharmaceuticals $REGNresults posted
LiraglutideNovo Nordisk A/S $NVOresults posted
NucresiranAlnylam Pharmaceuticals $ALNYenrollment 1750 β†’ 2250
RetatrutideEli Lilly and Company $LLYenrollment 320 β†’ 341
MAESTRA 2Incyte Corporation $INCYenrollment 466 β†’ 13
DELTA CARE 1LEO Pharmaenrollment 652 β†’ 552
BrivaracetamUCB Biopharma SRL $UCB.BRenrollment 70 β†’ 84
DuraSTARGlaxoSmithKline $GSKenrollment 90 β†’ 100
Citicoline eye drops 2%Omikron Italia S.r.l.enrollment 1000 β†’ 873
ZasocitinibTakeda $TAKenrollment 110 β†’ 210
EtentamigAbbVie $ABBVNot yet recruiting β†’ Recruiting
Bempedoic acidDaiichi Sankyo $4568.TNot yet recruiting β†’ Recruiting
Roflumilast Foam 0.3%Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Not yet recruiting β†’ Recruiting
MAESTRA 2Incyte Corporation $INCYRecruiting β†’ Active, not recruiting

Delay Index

Across 5,378 active trials registered more than a year ago, 46% have moved their readout date by more than 6 months since first registration.

Most often late

SponsorTrials>6 mo late
Acerta Pharma BV1191%
Ionis Pharmaceuticals, Inc. $IONS1283%
Taiho Oncology, Inc.1070%
Allist Pharmaceuticals, Inc.1267%
Seagen, a wholly owned subsidiary of Pfizer $PFE1267%

Most on time

SponsorTrialsOn time Β±1 mo
Qilu Pharmaceutical Co., Ltd.3388%
Ono Pharmaceutical Co., Ltd. $4528.T1385%
Shanghai JMT-Bio Inc.1283%
Biocad1283%
Dizal Pharmaceuticals1182%

FDA this week

New NDA/BLA approvals and Class I drug recalls (last 7 days), and manufacturing (CGMP) or trial-conduct warning letters (last 14 days).
TypeWhatCompanyDate
βœ“ ApprovalKLYGEFA (gefurulimab)ALEXION PHARM $AZN2026-11-13
βœ“ ApprovalPEBRILZO (pertuzumab)BIOCON BIOLOGICS INC2026-11-12

New Phase 3 trials Β· last 7 days

24 Phase 3 / 2-3 trials were first posted on ClinicalTrials.gov.
TrialSponsorAreaN
PINNACLE-MINovartis Pharmaceuticals $NVSCardio-Met10000
FrexalimabSanofi $SNYNeuro2500
FenebrutinibHoffmann-La Roche $RO.SWNeuro1800
Prevention of pneumococcal disease from 24 seroty…Reinovax Biologics Co., LTDInfectious1260
AMBITION 3Novo Nordisk A/S $NVOCardio-Met1200
AMBITION4Novo Nordisk A/S $NVOCardio-Met1060
PROST-3Tasly Biopharmaceuticals Co., Ltd.Other978
BerobenatidePfizer $PFECardio-Met900
DTaP-IPV-HB-PRP~T combined vaccineSanofi $SNYInfectious720
RC118(Dose 1) plus RC148(Dose 1)RemeGen Co., Ltd.Oncology680
ABBV-722AbbVie $ABBVImmuno580
SOLSTICE-HCMBristol-Myers Squibb $BMYCardio-Met500
AMBITION 2Novo Nordisk A/S $NVOCardio-Met450
NP-101Novatek PharmaceuticalsOncology381
TLX101-PxTelix Pharmaceuticals (Innovations) Pty LimitedOncology381

Post text

Ready to paste on LinkedIn or X.
πŸ“‘ DataCutoff Radar Report Β· 18 Nov 2026

⏱ 41 Phase 3 readouts due in the next 14 days (131 in 30):
β€’ 2026-11-18 β€” POETYK SjS-1 (Bristol-Myers Squibb $BMY, Immuno)
β€’ 2026-11-18 β€” Drugs-SNPs (Medicine Invention Design, Inc, Oncology)
β€’ 2026-11-20 β€” Pembrolizumab (Merck Sharp & Dohme LLC $MRK, Oncology)
β€’ 2026-11-21 β€” Cabergoline tablets (Changchun GeneScience Pharmaceutical Co., Ltd., Cardio-Met)
β€’ 2026-11-23 β€” Investigational varicella vaccine (GlaxoSmithKline $GSK, Infectious)

πŸ” Registry changes this week:
β€’ Nogapendekin alfa inbakicept (NAI) (ImmunityBio, Inc.): Not yet recruiting β†’ Withdrawn
β€’ NMS-03305293 (Nerviano Medical Sciences): Active, not recruiting β†’ Terminated
β€’ AB-3028 (Arsenal Biosciences, Inc.): Active, not recruiting β†’ Terminated
β€’ Debio 4326 (Debiopharm International SA): readout 2026-10 β†’ 2026-10-09 (+0.3 mo)

πŸ“‰ Delay Index: 46% of active trials (registered >1 yr ago) have pushed their readout >6 months.
Most often late: Acerta Pharma BV 91%, Ionis Pharmaceuticals, Inc. 83%, Taiho Oncology, Inc. 70%

βš• FDA: KLYGEFA approved (ALEXION PHARM); PEBRILZO approved (BIOCON BIOLOGICS INC)

Full report & live map: https://datacutoff.com/report/
Data: ClinicalTrials.gov, openFDA, fda.gov. Not investment advice.

Sources: ClinicalTrials.gov (U.S. NLM), openFDA and fda.gov warning letters. Primary completion dates are sponsor-reported and often estimates; readout = last primary-endpoint data collected, not results publication. For information only β€” not investment or medical advice. Disclaimer